RTW Biotech Opportunities (LSE:RTW) Stock Based Compensation: $0.0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:RTW RTW Biotech Opportunities Ltd LSE:RTW
40 GF Score
Price $2.40
! 2 Warning Signs
View Full Analysis

What is RTW Biotech Opportunities Stock Based Compensation?

RTW Biotech Opportunities LSE:RTW -1.23% 40 Stock Based Compensation is $0.0 Mil as of Dec. 2025. GuruFocus rates LSE:RTW with a GF Score™ of 40/100. The stock has 2 warning signs investors should review.

RTW Biotech Opportunities's Stock Based Compensation for the six months ended in Dec. 2025 was $0.0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was $0.0 Mil.

RTW Biotech Opportunities Stock Based Compensation Related Terms

RTW Biotech Opportunities Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for RTW Biotech Opportunities's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RTW Biotech Opportunities Stock Based Compensation Chart

RTW Biotech Opportunities Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

RTW Biotech Opportunities Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LSE:RTW
40GF Score
RTW Biotech Opportunities Ltd LSE:RTW
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RTW Biotech Opportunities Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.0 Mil.

What does a Stock Based Compensation of $0.0 Mil mean?
RTW Biotech Opportunities (LSE:RTW) has a Stock Based Compensation of $0.0 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for RTW Biotech Opportunities and its competitors.
Is RTW Biotech Opportunities' Stock Based Compensation too high?
RTW Biotech Opportunities' current Stock Based Compensation is $0.0 Mil. Overall, RTW Biotech Opportunities has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does RTW Biotech Opportunities' Stock Based Compensation compare to BLK and BX?
RTW Biotech Opportunities' Stock Based Compensation of $0.0 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for an Asset Management company?
A good Stock Based Compensation depends on the Asset Management industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for RTW Biotech Opportunities and its competitors. RTW Biotech Opportunities's current Stock Based Compensation is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RTW Biotech Opportunities stock overvalued right now?
RTW Biotech Opportunities (LSE:RTW) has a current Stock Based Compensation of $0.0 Mil. The current Stock Based Compensation is $0.0 Mil. RTW Biotech Opportunities' overall GF Score™ is 40/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For RTW Biotech Opportunities (LSE:RTW), the current Stock Based Compensation is $0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RTW Biotech Opportunities Business Description

Address St Julian’s Avenue, 1st Floor, Royal Chambers, St Peter Port, GGY, GY1 3JX
RTW Biotech Opportunities Ltd is a life sciences and investment fund focused on identifying transformative assets with high growth potential across the biopharma and medtech sectors. It is powering medical breakthroughs that have the potential to transform the wellbeing of people around the world. Its portfolio includes Neurology, Oncology, Inflammation, Cardiovascular, Metabolic, Pulmonary, Ophthalmology, Rare Disease, and Other. Geographically it operates in USA & Canada, the Rest of World, and UK & EU, with the majority of the revenue deriving from USA & Canada.
40GF Score

Get the complete analysis for LSE:RTW

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.40
Price